Alzheimer’s Disease: Early Diagnosis & Fundamental Therapeutics
- Alzheimer’s Disease: Early Diagnosis & Fundamental Therapeutics
- 알츠하이머병; 치료제; 치매; Alzheimer's Disease; amyloid; drug
- Issue Date
- Nano Korea 2012
- As the average life expectancy has been extended by the current state-of-art medical technologies, the elderly population is increasing rapidly. The world is now facing the ‘ageing era’, which comes with social issues like Alzheimer’s disease (AD). AD is the most common and fatal neurodegenerative disorder with disastrous effects on the senior population (Maslow, 2008). About 10% of people over 65 years old and half of those over 85 suffer from AD. Prevalence of this progressive disorder increases with ageing, affecting 3% of people between 60-69-year-olds, 5% of those between 70-79 and 30-50% of those between 80-89. Typical symptoms of AD are memory loss, cognitive impairment and behavior dysfunction to death. In many cases, AD patients develop physiological dysfunctions such as swallowing, balance and bladder control. Psychological symptoms such as depression are often associated with the disorder. According to the progression of the disorder, patients are categorized into seven stages; no impairment, very mild decline, mild decline, moderate decline, moderately severe decline, severe decline and very severe decline.
- Appears in Collections:
- KIST Publication > Conference Paper
- Files in This Item:
There are no files associated with this item.
- RIS (EndNote)
- XLS (Excel)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.